Crystallization method and bioavailability
Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl) phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.
1. A method of treating psoriatic arthritis, said method comprising the step of administering to a psoriatic arthritis patient a therapeutically effective amount of a crystalline molecular complex of zoledronic acid, lysine and water,
and an additional lysine apart from the lysine in the crystalline molecular complex,
wherein the lysine is selected from D,L-lysine or L-lysine.
2. A method of treating psoriatic arthritis according to claim 1 , wherein the lysine is D,L-lysine.
3. A method of treating psoriatic arthritis according to claim 1 , wherein the lysine is L-lysine.
4. A method of treating psoriatic arthritis according to claim 1 , wherein the crystalline molecular complex is administered as a pharmaceutical composition comprising the crystalline molecular complex and a pharmaceutical carrier.
5. A method of treating psoriatic arthritis according to claim 2 , wherein the crystalline molecular complex is administered as a pharmaceutical composition comprising the crystalline molecular complex and a pharmaceutical carrier.
6. A method of treating psoriatic arthritis according to claim 3 , wherein the crystalline molecular complex is administered as a pharmaceutical composition comprising the crystalline molecular complex and a pharmaceutical carrier.
7. A method of treating psoriatic arthritis according to claim 5 , wherein the pharmaceutical composition further comprises additional D,L-lysine apart from the D,L-lysine in the crystalline molecular complex.
8. A method of treating psoriatic arthritis according to claim 7 , wherein the D,L-lysine is D,L-lysine monohydrate.
9. A method of treating psoriatic arthritis according to claim 6 , wherein the pharmaceutical composition further comprises additional L-lysine apart from the L-lysine in the crystalline molecular complex.
10. A method of treating psoriatic arthritis according to claim 4 , wherein the pharmaceutical composition is an oral dosage form.
11. A method of treating psoriatic arthritis according to claim 10 , wherein the oral dosage form is selected from a tablet and a capsule.
12. A method of treating psoriatic arthritis according to claim 5 , wherein the pharmaceutical composition is an oral dosage form.
13. A method of treating psoriatic arthritis according to claim 12 , wherein the oral dosage form is selected from a tablet and a capsule.
14. A method of treating psoriatic arthritis according to claim 6 , wherein the pharmaceutical composition is an oral dosage form.
15. A method of treating psoriatic arthritis according to claim 14 , wherein the oral dosage form is selected from a tablet and a capsule.
16. A method of treating psoriatic arthritis according to claim 4 , wherein the pharmaceutical composition is an oral dosage form.
17. A method of treating psoriatic arthritis according to claim 16 , wherein the oral dosage form is selected from a tablet and a capsule.
18. A method of treating psoriatic arthritis according to claim 7 , wherein the pharmaceutical composition is an oral dosage form.
19. A method of treating psoriatic arthritis according to claim 18 , wherein the oral dosage form is selected from a tablet and a capsule.